North America Immuno-Oncology Market

North America Immuno-Oncology Market Size (2023 to 2028)

The size of the immune-oncology market in the North American region is forecasted to be growing at a CAGR of 12.58% from 2023 to 2028 and worth USD 3.12 billion by 2028 from USD 1.73 billion in 2023.

Y-O-Y rise in the prevalence of cancer is one of the primary factors driving the immuno-oncology market forward in the North American region. Cancer is a dangerous disease that develops through the multi-stage carcinogenesis process. It has become the leading cause of death globally, accounting for 9.6 million deaths in 2018. According to GLOBOCAN, cancer cases will rise to approximately 30 million by 2040 from 20 million in 2019. As a result, the growth in the incidence and prevalence of cancer has resulted in a need to conduct extensive research for diagnosis and treatment, and immuno-oncology assays form an essential part of this research.

In recent years, immunomodulatory drugs such as thalidomide, lenalidomide, and pomalidomide have been the most effective treatments. In addition, newer drugs like monoclonal antibodies and HDAC inhibitors, designed to inhibit multiple myeloma-related receptors, are anticipated to bring in recent market trends. Therefore, developing treatments for different types of cancer increased the demand for Immuno-oncology (IO). Furthermore, increasing investment by the government and several pharmaceutical companies in research & development for treating cancer is predicted to drive the immuno-oncology (IO) market over the forecast period.  As a result, immuno-oncology has proved essential for understanding cancer signatures and developing customized treatments.

The immuno-oncology market in the North American region is further anticipated to be driven by the growing older population. The market for immuno-oncology will grow because of rising cancer incidence among the aging population. According to the Union for International Cancer Control, nearly 60% of people will receive a cancer diagnosis in 2020. During the forecast period, this is also anticipated to be the driving force behind the development of immuno-oncology drugs. Since obesity is a known risk factor for colorectal cancer, adopting unhealthy lifestyles and rising obesity rates will increase the demand for immune-oncology treatments. In addition, new and cutting-edge technologies are being accepted in immuno-oncology treatment because of the FDA's growing approval for sophisticated immuno-oncology drugs.

On the other hand, the high capital investment required, strict FDA guidelines for the drug approval of the new drug, the adverse effect after the treatment, and lack of skilled labor are the major factors hindering the growth of the immune-oncology market in the North American region. In addition, high costs of the drugs are a significant challenge faced by patients. The absence of cost-effective drugs has influenced the population's health conditions and reduced life expectancy.

This research report on the North American immuno-oncology market has been segmented and sub-segmented into the following categories.

By Product & Service:

• Consumables

• Instruments

• Software

By Technology:

• PCR

• Immunoassay

• NGS

• ISH

• Flow Cytometry

By Application:

• Research Applications

• Clinical Diagnostics

By Country:

• The United States

• Canada

• Rest of North America

The North American region accounted for the majority of the share of the global immune-oncology market in 2022. The adoption of cancer immunotherapies over conventional cancer treatments, technology advancements such as automated immuno-oncology assays, the development of bioinformatics tools, and the rise in demand for personalized medicine are only a few factors contributing to this expansion. The American Cancer Society estimates that there will be 1,806,599 new cancer cases and 606,520 cancer deaths in the country in 2020.

In the R&D for drugs to treat illnesses including cancer and cardiovascular ailments, immuno-oncology is employed more frequently. The xMAP Multiplex Assay offers a platform for cancer biomarker assays compatible with plasma, serum, cultured cells, and other biological materials. The American Association for Cancer Research created the multiplex immunoassay that assisted in analyzing acquired resistance to receptor tyrosine kinase (RTK) inhibitors. Drugs for the treatment of cancer are developed using RTK. A combined immunotherapy approach was used to treat metastatic kidney cancer in the United States. One of the dual immunotherapies, ipilimumab/nivolumab, is now the national standard of care for treating kidney cancer.

KEY MARKET PLAYERS:

AstraZeneca Plc, Bristol-Myers Squibb, Celgene Corporation, Eli Lilly and Company, Merck & Co., F. Hoffmann-La Roche AG, Johnson & Johnson, Novartis International AG, AbbVie Inc., Pfizer Inc., Gilead Sciences Inc., Prometheus Therapeutics & Diagnostics, Aduro BioTech, Galena Biopharma, Bavarian Nordic, Takeda, Spectrum Pharmaceuticals and GlaxoSmithKline are a few of the companies operating in the North American immune-oncology market profiled in this report.